Results 1 to 10 of about 5,881 (166)

Exportin 1 (XPO1) Expression and Effectiveness of XPO1 Inhibitor Against Canine Lymphoma Cell Lines [PDF]

Veterinary Sciences
Lymphoma is the most common neoplasm of lymphoid tissues in dogs. Exportin 1 (XPO1) is an important major nuclear receptor for exporting proteins and RNA species.
Hardany Primarizky, Satoshi Kambayashi, Kenji Baba, Kenji Tani, Masaru Okuda   +4 more
doaj   +5 more sources

Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia [PDF]

Journal of Hematology & Oncology, 2021
Background Exportin 1 (XPO1/CRM1) is a key mediator of nuclear export with relevance to multiple cancers, including chronic lymphocytic leukemia (CLL). Whole exome sequencing has identified hot-spot somatic XPO1 point mutations which we found to disrupt ...
Janek S. Walker, Zachary A. Hing, Bonnie Harrington, Jordan Baumhardt, Hatice Gulcin Ozer, Amy Lehman, Brian Giacopelli, Larry Beaver, Katie Williams, Jordan N. Skinner, Casey B. Cempre, Qingxiang Sun, Sharon Shacham, Benjamin R. Stromberg, Matthew K. Summers, Lynne V. Abruzzo, Laura Rassenti, Thomas J. Kipps, Sameer Parikh, Neil E. Kay, Kerry A. Rogers, Jennifer A. Woyach, Vincenzo Coppola, Yuh Min Chook, Christopher Oakes, John C. Byrd, Rosa Lapalombella   +26 more
doaj   +5 more sources

Targeting the nuclear export receptor exportin‐1 in acute myeloid leukaemia: From biology to clinical translation [PDF]

Clinical and Translational Medicine
Background Exportin‐1 (XPO1), a key regulator of nucleocytoplasmic transport, is frequently dysregulated in acute myeloid leukemia (AML) and contributes to leukemogenesis, disease progression and therapeutic resistance.
Yifan Liu, Xiaoya Yun, Weidong Ding, Suxiao Li, Hui Liu   +4 more
doaj   +2 more sources

Synergistic Antitumor Activity of HAT Inhibitor A485 and XPO1 Inhibitor KPT8602 in Multiple Myeloma. [PDF]

Cancer Med
ABSTRACT Background Multiple myeloma (MM) remains the second most common hematologic malignancy, necessitating the identification of novel therapeutic targets. MM is characterized by a distinct epigenetic landscape driven by aberrant chromatin activation and super‐enhancer addiction.
Xu H, Wu W, Jiang Y, Wang J, Zhai Y, Zhao Z.   +5 more
europepmc   +2 more sources

CCT3-mediated regulation of XPO1/RB1 axis stability promotes cellular senescence and tumor progression in clear cell renal carcinoma [PDF]

iScience
Summary: Cellular senescence’s role in clear cell renal carcinoma (ccRCC) remains unclear. We identify CCT3 as a driver of ccRCC progression by enhancing XPO1 stability via correct folding, confirmed by Co-IP and GST pull-down.
Yilong Cao, Chao Xu, Yuepeng Liu, Bei Shi, Xiaoling Li, Jiehan Li, Bowei Zhang, Zeyuan Zhang, Shengtao Dai, Qingyun Sun, Junfei Gu   +10 more
doaj   +2 more sources

XPO1 serves as a prognostic marker involving AKT/MAPK/TGFBR1 pathway in OSCC

Cancer Medicine
Background Exportin 1 (XPO1) is a nuclear export protein that facilitates the transportation of various substances. XPO1 promotes tumor development as a poor prognostic factor in a variety of tumors and is a therapeutic target for screening inhibitors ...
Tong Su, Kun Xia
exaly   +2 more sources

NRF2 activators and the inhibitor of nuclear export, selinexor, restrict coronaviruses by targeting a network involving ACE2, TMPRSS2, and XPO1 through an NRF2-independent mechanism [PDF]

Communications Biology
Nuclear factor erythroid 2–related factor 2 (NRF2) plays important roles in antiviral host cell defenses. We assessed the potential of the NRF2 activators 4-octyl itaconate (4OI), bardoxolone (BARD), and sulforaphane (SFN), and the exportin-1 (XPO1 ...
Fakhar H. Waqas, Leandro Silva da Costa, Francisco J. Zapatero-Belinchón, Madalina E. Carter-Timofte, Lisa Lasswitz, Demi van der Horst, Rebecca Möller, Julia Dahlmann, Ruth Olmer, Robert Geffers, Gisa Gerold, David Olagnier, Frank Pessler   +12 more
doaj   +2 more sources

Exportin 1 as a Therapeutic Target to Overcome Drug Resistance in Lung Cancer [PDF]

Cells
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality, with therapeutic resistance continuing to limit long-term responses.
Maria Vittoria Di Marco, Alessandro Gasparetto, Roberto Chiarle, Claudia Voena   +3 more
doaj   +2 more sources

Mobilization of nuclear antiviral factors by exportin XPO1 via the actin network inhibits RNA virus replication. [PDF]

PLoS Pathogens
The intricate interplay between +RNA viruses and their hosts involves the exploitation of host resources to build virus-induced membranous replication organelles (VROs) in cytosol of infected cells.
Biao Sun, Cheng-Yu Wu, Paulina Alatriste Gonzalez, Peter D Nagy   +3 more
doaj   +2 more sources

Inhibition of XPO1 impairs cholangiocarcinoma cell proliferation by triggering p53 intranuclear accumulation

Cancer Medicine, 2023
Background XPO1 mediates the nuclear export of several proteins, mainly tumor suppressors. KPT‐330 (Selinexor) is a selective inhibitor of XPO1 that has demonstrated good therapeutic effects in hematologic cancers.
Cheng Zhao, Ben Ma, Zi‐yi Yang, Ou Li, Shi‐lei Liu, Li‐jia Pan, Wei Gong, Ping Dong, Yi‐jun Shu   +8 more
doaj   +1 more source